Create Free Account

By creating account you will get access to hot stocks & personalised emails

Zelira Therapeutics Ltd

Healthcare AU ZLD

0.71AUD
0.01(1.43%)

Last update at 2024-04-24T00:47:00Z

Day Range

0.710.71
LowHigh

52 Week Range

0.683.35
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -6.26873M -12.41352M -8.54908M -7.01504M -3.56780M
Minority interest 0.70M 0.47M - - -
Net income -5.57301M -11.94530M -8.54908M -7.01504M -2.89722M
Selling general administrative 3.06M 6.08M 4.49M 1.97M 1.25M
Selling and marketing expenses 0.07M 0.72M 0.51M - -
Gross profit -0.06144M 0.60M 0.44M 0.44M 0.86M
Reconciled depreciation 0.55M 0.59M 0.47M 0.28M -
Ebit -5.92556M -12.35967M -8.50645M -7.00270M -4.23838M
Ebitda -5.38033M -11.77113M -8.03220M -6.72765M -4.23838M
Depreciation and amortization 0.55M 0.59M 0.47M 0.28M -
Non operating income net other - - - - -
Operating income -7.16418M -13.20630M -9.37993M -7.00270M -4.23838M
Other operating expenses 6.49M 13.91M 9.17M 7.94M 4.24M
Interest expense 0.08M 0.05M 0.04M 0.01M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.08M 0.01M 0.00072M 0.12M 0.19M
Net interest income -0.07653M -0.04325M -0.04190M -0.01234M 0.09M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.72M 0.86M 1.30M 0.94M -0.67058M
Total revenue 0.30M 1.54M 0.66M 0.66M 0.86M
Total operating expenses 7.20M 14.25M 10.20M 7.94M 4.24M
Cost of revenue 0.36M 0.94M 0.23M 0.23M -
Total other income expense net 1.07M 1.28M 1.25M 0.93M 0.67M
Discontinued operations - - - - -
Net income from continuing ops -6.26873M -12.41352M -8.54908M -7.01504M -3.56780M
Net income applicable to common shares -5.57301M -11.94530M -8.54908M -7.01504M -3.56780M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 33.89M 37.70M 39.37M 35.79M 3.52M
Intangible assets 0.81M 0.97M 1.12M 1.28M 1.28M
Earning assets - - - - -
Other current assets 0.11M 0.27M 0.21M 0.14M -
Total liab 2.18M 2.01M 1.54M 1.24M 0.41M
Total stockholder equity 31.80M 35.20M 37.83M 34.55M 3.11M
Deferred long term liab - - - - -
Other current liab 0.14M 0.12M 0.09M 0.05M 0.05M
Common stock 45.52M 43.75M 36.65M 26.08M 13.82M
Capital stock 45.52M 43.75M 36.65M 26.08M 13.82M
Retained earnings -44.76727M -39.19426M -27.24895M -18.69988M -11.68027M
Other liab - - - - -
Good will 30.75M 30.75M 30.75M 30.75M 30.75M
Other assets 0.04M 0.06M 0.10M 0.11M -
Cash 0.15M 2.75M 4.97M 1.70M 3.07M
Cash and equivalents - - - - 3.07M
Total current liabilities 1.88M 1.63M 1.08M 0.67M 0.41M
Current deferred revenue -0.14253M -0.11671M -0.09053M - -0.11086M
Net debt 0.29M -2.24550M -4.42004M -1.06472M -2.44080M
Short term debt 0.14M 0.12M 0.09M 0.06M 0.06M
Short long term debt - - - - -
Short long term debt total 0.44M 0.50M 0.55M 0.63M 0.63M
Other stockholder equity -0.57018M 30.65M 28.43M 27.17M 0.96M
Property plant equipment 0.52M 0.85M 1.24M 1.58M 0.03M
Total current assets 1.77M 5.08M 6.09M 1.83M 3.12M
Long term investments 0.04M 0.06M 0.17M 0.35M 0.36M
Net tangible assets 0.24M 3.49M 5.96M 2.52M 3.11M
Short term investments - - -0.09985M -0.10822M -
Net receivables -0.00109M 0.26M 0.06M 0.06M 0.05M
Long term debt - - - - -
Inventory 1.53M 1.96M 0.87M -0.06414M -
Accounts payable 1.74M 1.51M 0.98M 0.56M 0.41M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 31.05M 30.65M 28.43M 27.17M 0.96M
Additional paid in capital - - - - -
Common stock total equity - - - 26.08M 13.82M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -32.07635M -32.56124M -33.17553M -33.84767M -32.02560M
Deferred long term asset charges - - - - -
Non current assets total 32.12M 32.63M 33.28M 33.96M 0.39M
Capital lease obligations 0.44M 0.50M 0.55M 0.63M -
Long term debt total 0.30M 0.38M 0.46M 0.57M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments 2.83M -0.20778M 1.38M 1.11M 0.73M
Change to liabilities 0.23M 0.53M 0.43M -0.05011M 0.30M
Total cashflows from investing activities 2.83M -0.20778M 1.38M 1.11M 0.73M
Net borrowings - - - - -
Total cash from financing activities 1.77M 7.10M 10.53M 4.50M 4.50M
Change to operating activities - - - - -
Net income -5.57301M -11.94530M -8.54908M -7.01504M -3.56780M
Change in cash -2.60020M -2.22471M 3.27M -1.37609M -2.61260M
Begin period cash flow 2.75M 4.97M 1.70M 3.07M 5.69M
End period cash flow 0.15M 2.75M 4.97M 1.70M 3.07M
Total cash from operating activities -7.24908M -9.42722M -8.61658M -6.93628M -7.79786M
Issuance of capital stock 1.77M 7.10M 10.62M 4.79M -
Depreciation 0.55M 0.59M 0.47M 0.28M 0.28M
Other cashflows from investing activities 2.83M -0.20778M 1.38M 0.93M 0.76M
Dividends paid - - - - -
Change to inventory 0.36M -1.08956M -0.86759M -0.86759M -0.86759M
Change to account receivables 0.28M -0.12098M -0.11590M -0.08425M 0.04M
Sale purchase of stock 1.77M 7.10M -0.08800M -0.28670M -0.28670M
Other cashflows from financing activities 2.83M -0.20778M 1.38M 1.11M 0.73M
Change to netincome -3.08462M 2.62M 0.02M -0.06192M -0.11907M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.02M 0.03M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.63M -1.21054M -0.98349M -0.08425M -2.08148M
Stock based compensation 0.40M 2.69M 1.30M 0.54M -
Other non cash items -2.22130M 1.93M -0.54176M -0.19628M 3.57M
Free cash flow -7.24908M -9.42722M -8.61658M -6.95224M -7.82608M

Fundamentals

  • Previous Close 0.70
  • Market Cap8.06M
  • Volume565
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.13858M
  • Revenue TTM0.28M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM -0.32795M
  • Diluted EPS TTM-3.24

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ZLD
Zelira Therapeutics Ltd		 0.01 1.43% 0.71 - - 28.07 0.33 34.03 -0.2627
CSL
CSL Ltd		 6.61 2.40% 282.08 35.34 31.35 9.60 5.16 10.91 34.93
TLX
Telix Pharmaceuticals Ltd		 0.78 5.53% 14.88 744.00 21.01 8.47 28.69 8.21 177.65
NEU
Neuren Pharmaceuticals Ltd		 0.17 0.88% 19.45 15.71 38.46 11.63 13.15 10.65 12.39
MSB
Mesoblast Ltd		 0.01 1.67% 0.92 - 769.23 116.88 1.12 126.11 -19.3368

Reports Covered

Stock Research & News

View All

Profile

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. It also provides over the counter products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.

Zelira Therapeutics Ltd

101 St George's Terrace, Perth, WA, Australia, 6000

Key Executives

Name Title Year Born
Mr. Osagie O. Imasogie Esq. Founder & Chairman 1962
Dr. Oludare Odumosu MD, Global CEO & Director NA
Mr. Timothy Ryan Slate Non-Exec. Director & Company Sec. NA
Mr. Rahul Ganesan VP of Fin. & Accounting NA
Mr. Greg Blake VP of Global and Head of Commercial & Partnering NA
Dr. Patty Washer Clinical Trial Consultant NA
Mr. Greg Blake Executive Director NA
Mr. Timothy Ryan Slate Company Secretary & Non-Executive Director NA
Mr. Rahul Ganesan Vice President of Finance & Accounting NA
Mr. Greg Blake Executive Director NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.